#1 Clinical Trials Search in Europe

Crizotinib

Crizotinib is an oral medication being studied in clinical trials for its potential to treat various types of cancer, particularly those with specific genetic alterations. This article summarizes key findings from recent clinical trials investigating crizotinib’s safety, efficacy, and pharmacokinetics in different patient populations and cancer types.

Table of Contents

What is Crizotinib?

Crizotinib, also known by its brand name XALKORI, is a targeted cancer therapy drug used primarily in the treatment of certain types of non-small cell lung cancer (NSCLC)[1]. It belongs to a class of medications called kinase inhibitors, which work by blocking specific proteins that contribute to cancer growth[2].

How Crizotinib Works

Crizotinib specifically targets cancers that have a genetic alteration involving the anaplastic lymphoma kinase (ALK) gene. This gene produces a protein that, when altered, can lead to uncontrolled cell growth and cancer. By inhibiting the ALK protein, crizotinib can help slow or stop the growth of cancer cells[3].

In addition to targeting ALK, crizotinib also inhibits other proteins that may be involved in cancer growth, such as the ROS1 and MET proteins. This makes it potentially effective against cancers with different genetic alterations[2].

Conditions Treated by Crizotinib

Crizotinib is primarily used to treat:

  • Non-small cell lung cancer (NSCLC): Specifically, NSCLC that is ALK-positive or ROS1-positive[1]
  • Anaplastic large cell lymphoma (ALCL): A rare type of blood cancer[2]
  • Inflammatory myofibroblastic tumors (IMT): A rare type of soft tissue tumor[2]

Research is ongoing to explore its potential in treating other types of cancers with specific genetic alterations[2].

How Crizotinib is Administered

Crizotinib is typically taken orally in the form of capsules. The standard dose for adults is usually 250 mg twice daily, taken continuously[1]. However, the exact dosage may vary depending on the patient’s condition, response to treatment, and any side effects experienced.

For patients who have difficulty swallowing capsules, such as some pediatric patients, alternative formulations are being developed. These include an oral solution and an encapsulated microsphere (eMS) formulation, which is being studied to improve palatability and ease of administration[4].

Efficacy of Crizotinib

Clinical trials have shown that crizotinib can be highly effective in treating ALK-positive NSCLC. In a study comparing crizotinib to standard chemotherapy in previously untreated East Asian patients with ALK-positive NSCLC, crizotinib demonstrated superior efficacy in several key areas[1]:

  • Progression-free survival (PFS): Crizotinib significantly prolonged the time before the cancer progressed compared to chemotherapy.
  • Objective response rate (ORR): A higher percentage of patients treated with crizotinib showed a significant reduction in tumor size.
  • Quality of life: Patients on crizotinib reported better overall quality of life and improvement in lung cancer symptoms compared to those on chemotherapy.

Side Effects and Safety

Like all medications, crizotinib can cause side effects. Some of the most common side effects reported in clinical trials include[1][5]:

  • Visual disturbances: Such as blurred vision or seeing flashes of light
  • Gastrointestinal issues: Including nausea, vomiting, diarrhea, and constipation
  • Fatigue
  • Edema: Swelling, particularly in the legs and feet
  • Liver enzyme abnormalities: Which may require regular blood tests to monitor

More serious but less common side effects can include lung inflammation (pneumonitis) and heart rhythm changes. It’s important for patients to report any side effects to their healthcare provider promptly[5].

Ongoing Research and Combination Therapies

Researchers are continually studying crizotinib to understand its full potential and to explore ways to enhance its effectiveness. Some areas of ongoing research include:

  • Combination therapies: Studies are investigating the use of crizotinib in combination with other cancer treatments. For example, a study is looking at combining crizotinib with pembrolizumab, an immunotherapy drug, in ALK-positive NSCLC patients[5].
  • Expanded use: Researchers are exploring the use of crizotinib in other types of cancers that have ALK, ROS1, or MET alterations[2].
  • Improved formulations: Work is being done to develop new formulations of crizotinib that may be easier to take, especially for patients who have difficulty swallowing capsules[4].

Important Considerations for Patients

If you’re considering or currently taking crizotinib, here are some important points to keep in mind:

  • Genetic testing: Crizotinib is most effective in cancers with specific genetic alterations. Your doctor will likely recommend genetic testing of your tumor to determine if crizotinib is appropriate for you[1].
  • Regular monitoring: While on crizotinib, you’ll need regular check-ups and tests to monitor your response to the treatment and watch for any side effects[5].
  • Drug interactions: Crizotinib can interact with other medications. Always inform your healthcare provider about all medications, supplements, and herbal products you’re taking[5].
  • Pregnancy and breastfeeding: Crizotinib may harm an unborn baby. If you’re pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor before starting treatment.
  • Clinical trials: If standard treatments aren’t working for you, you might be eligible for a clinical trial studying new ways to use crizotinib or combining it with other treatments[5].

Remember, while this information provides a general overview, your healthcare team is the best source of information about how crizotinib relates to your specific situation. Don’t hesitate to ask questions and discuss any concerns you may have with your doctor.

Aspect Details
Main Indications Non-small cell lung cancer (NSCLC), advanced lymphomas, solid tumors with ALK or ROS1 genetic changes
Mechanism of Action Inhibition of ALK, ROS1, and MET proteins involved in cancer cell growth
Administration Oral capsules, typically 250 mg twice daily
Key Outcomes Measured Objective Response Rate (ORR), Progression-Free Survival (PFS), safety profile
Special Populations Studied Patients with hepatic impairment, renal impairment, pediatric patients
Ongoing Research Focus Bioequivalence of new formulations, pharmacogenomics, long-term safety and efficacy

FAQ

  • What types of cancer is crizotinib being studied for? Crizotinib is being studied for several types of cancer, including non-small cell lung cancer (NSCLC), advanced lymphoma, and other solid tumors with specific genetic changes like ALK rearrangements or ROS1 translocations.
  • How does crizotinib work? Crizotinib works by blocking certain proteins, such as ALK, ROS1, and MET, which may be involved in cancer cell growth. By inhibiting these proteins, crizotinib may help slow or stop the growth of cancer cells.
  • What are some common side effects of crizotinib? While specific side effects vary between trials, common adverse events associated with crizotinib include gastrointestinal issues, liver function abnormalities, and changes in blood cell counts. The safety profile is being closely monitored in ongoing studies.
  • How is crizotinib administered? Crizotinib is typically administered orally, usually as capsules taken twice daily. The exact dosage and schedule may vary depending on the specific trial and patient factors.
  • Are there any special populations being studied with crizotinib? Yes, several trials are investigating crizotinib in special populations, including patients with hepatic impairment, renal impairment, and pediatric patients. These studies aim to understand how the drug behaves in different patient groups and optimize its use.

Ongoing Clinical Trials on Crizotinib

  • Study Comparing Ensartinib and Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Italy The Netherlands Poland +1

  • Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia France Germany Greece Italy The Netherlands +4

  • Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Greece Hungary Italy +4

  • Study on Brigatinib, Ceritinib, and Alectinib for Patients with Advanced ALK+ Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • ALK rearrangement: A genetic alteration in the ALK (anaplastic lymphoma kinase) gene that can lead to abnormal cell growth and cancer.
  • ROS1 translocation: A genetic change where the ROS1 gene is abnormally fused with another gene, potentially leading to cancer development.
  • Bioequivalence: The property of two drug formulations having the same biological effect and availability in the body.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing.
  • Adverse Drug Reaction (ADR): An unwanted or harmful reaction experienced following the administration of a drug or combination of drugs.
  • Single Nucleotide Polymorphism (SNP): A variation in a single DNA building block that occurs at a specific position in the genome.
  • Hepatic Impairment: Reduced liver function that may affect how drugs are processed in the body.
  • Renal Impairment: Decreased kidney function that can impact drug elimination from the body.

References

  1. https://clinicaltrials.gov/study/NCT01639001
  2. https://clinicaltrials.gov/study/NCT02034981
  3. https://clinicaltrials.gov/study/NCT01121588
  4. https://clinicaltrials.gov/study/NCT04856293
  5. https://clinicaltrials.gov/study/NCT02511184